Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk said its Wegovy injection reduced body mass index and obesity rates in children in a clinical trial, according to company reporting covered by CNBC, Quartz, WSJ, Financial Times and The New York Times. The New York Times and Financial Times identified the studied group as children as young as six years old. CNBC, Quartz and WSJ headline the trial results as successful. Separately, Reuters reported real-world data showing adults taking Novo's Wegovy pill lost about six percent of body weight over three months. Doctors remain divided on how widely GLP-1 drugs should be used in young children, per abc7.com.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Novo Nordisk reported that its Wegovy injection lowered BMI and obesity rates in children in a trial.
- ✓ The trial included children as young as six years old.
- ✓ Real-world data showed adults taking Novo's Wegovy pill lost about six percent of weight in three months.
What changed
Novo Nordisk disclosed trial evidence that its Wegovy injection cuts obesity in children as young as six, expanding the drug's pediatric evidence beyond adolescents.
Live updates
-
Novo Nordisk reports Wegovy lowers BMI and obesity in children as young as six in trial
Novo Nordisk said its Wegovy injection reduced body mass index and obesity rates in children in a clinical trial, according to company reporting covered by CNBC, Quartz, WSJ, Financial Times and The New York Times. The New York Times and Financial Times identified the studied group as children as young as six years old. CNBC, Quartz and WSJ headline the trial results as successful. Separately, Reuters reported real-world data showing adults taking Novo's Wegovy pill lost about six percent of body weight over three months. Doctors remain divided on how widely GLP-1 drugs should be used in young children, per abc7.com.
Why it matters
Wegovy is already approved for weight management in adolescents, but this trial extends the evidence base down to elementary-age children. Regulatory acceptance could open a major new patient group for Novo Nordisk and intensify debate over medicating obesity in early childhood. The pill data from Reuters concerns a different formulation and adult population, so it does not confirm pediatric results. Long-term safety and durability of weight loss in children remain unresolved.
What is confirmed
- Novo Nordisk reported that its Wegovy injection lowered BMI and obesity rates in children in a trial.
- The trial included children as young as six years old.
- Real-world data showed adults taking Novo's Wegovy pill lost about six percent of weight in three months.
Still unconfirmed
- Doctors are split on how widely GLP-1 drugs should be used in younger children.
What to watch next
- Regulatory decisions on pediatric Wegovy approvals
- Publication of full pediatric trial data and long-term safety results
- Further clinical guidance on GLP-1 use in children under twelve
confidence 50%Sources used for this update (7)
- CNBC — Novo says Wegovy injection lowers BMI and obesity rates in children in trial
- Reuters — Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
- The New York Times — New Data Paves the Way for Weight-Loss Drugs in Children as Young as 6
- WSJ — Weight-Loss Drugs for Elementary-Age Children Succeed in Study
- Financial Times — Six-year-olds: Novo’s new frontier for weight-loss drugs
- Quartz — Novo Nordisk's weight loss injection cut obesity in young children, trial shows
- abc7.com — GLP-1s could be effective in children as young as 6. Should kids be using them?
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community